• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·UMCN
Share

UMC, Inc. Stocks

$ 0.06Last Updated 29.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 39.36M

$ 0.06
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

UMC, Inc. delivers vital administrative and financial support services to healthcare providers. Their extensive suite of solutions includes the precise coding and submission of medical insurance claims, secure management of electronic patient records, thorough evaluation of service pricing (chargemaster review), competitive cost analysis, and complete oversight of patient billing and collections. The company's customer base predominantly comprises hospitals, medical clinics, and individual physician practices located throughout the United States. Founded in 1989, the organization initially operated under the name United Medicorp, Inc., before officially rebranding as UMC, Inc. in May 2007. Its corporate headquarters are situated in Pampa, Texas.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overpriced

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.08.2026 04:17

Not a White Knight: How the “Savior” of “AI-Nostradamus” Makes Money by Sensing Trouble

01.08.2026 03:08

Trump Ordered New Strikes Against Iran — WSJ

01.08.2026 02:07

The Nasdaq Composite had its worst July in 20 years due to a plunge in chipmaker stocks

01.08.2026 01:30

Alibaba Supplied 20,000 Nvidia Chips to the Creator of Kimi K3 — Bloomberg

01.08.2026 00:22

"These scars have cost us dearly": "AI Nostradamus" promised not to borrow money anymore

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026